GNGanesh Narayanasamy

Ganesh Narayanasamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ganesh Narayanasamy has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Jose Penagaricano

    University of Arkansas for Medical Sciences, Little Rock, AR

    7 shared publications
  • Steven Morrill

    Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America

    6 shared publications
  • Jose Penagaricano

    Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    5 shared publications
  • Milan Bimali

    Department of Biostatistics University of Arkansas for Medical Sciences Little Rock Arkansas USA

    4 shared publications
  • Sanjay Maraboyina

    Department of Radiation Oncology, University of Arkansas for Medical Sciences, AR, United States of America

    4 shared publications
  • Dharmin Desai

    Memorial Hospital Chattanooga TN USA

    3 shared publications

Latest Publications

  • Open Access

    Producing high quality cranial SRS plans with 4Pi planning technique in a commercial clinical solution

    by Ganesh Narayanasamy, Nishan Shrestha, Milan Bimali, Fen Xia, Zhong Su

    Purpose: To generate high‐quality stereotactic radiosurgery (SRS) plans for single cranial lesions using 4Pi planning technique and compare these to our clinical “status quo” plans. Methods: Eighteen vestibular schwannoma (VS) patients previously planned with Varian Eclipse RapidArc and treated on a Varian TrueBeam using 6FFF MV photon beams were randomly selected. This cohort was replanned in Brainlab Elements Cranial SRS using an automatic 4Pi trajectory optimization technique (“Elements 4Pi”). “Elements ArcMatch” plans were also created, which utilized the identical arc geometry as the clinical plans in Eclipse, that is, used identical table angles, gantry start and stop angles, and collimator angles to isolate the inherent differences between the two treatment planning systems. SRS plan evaluation metrics included the Inverse Paddick conformity index (IPCI), gradient index (GI), max doses to the brainstem and ipsilateral cochlea, and number of monitor units (MUs). Pairwise comparisons between Eclipse and Elements 4Pi plans were performed using Wilcoxon signed rank test. For three‐way comparisons with Elements‐ArcMatch plans, the difference in distribution of SRS metrics was assessed first based on Friedman's test, followed by pairwise comparison if the findings from Friedman's test met statistical significance. A two‐sided p ‐value of 0.05 was used to determine statistical significance. Results: While both Elements 4Pi and Elements ArcMatch plans had significantly lower GI, MU, and max doses to the brainstem and ipsilateral cochlea compared to Eclipse plans ( p ‐values < 0.05), Elements 4Pi also had significantly lower IPCI values. Conclusion: The automation in Brainlab Elements Cranial SRS outperformed manual expert planning and produced collision‐free and clinically deliverable plans for single targets with significantly better dose conformality, dose gradient, and lower dose to normal organs while using lower MUs compared to clinically delivered Eclipse plans.


  • Cleaning the dose falloff with low modulation in SBRT lung plans

    by Andrew J Boria, Ganesh Narayanasamy, Milan Bimali, Sanjay Maraboyina, Faraz Kalantari, Pouya Sabouri, Zhong Su

    Purpose. This dosimetric study is intended to lower the modulation factor in lung SBRT plans generated in the Eclipse TPS that could replace highly modulated plans that are prone to the interplay effect. Materials and methods. Twenty clinical lung SBRT plans with high modulation factors (≥4) were replanned in Varian Eclipse TPS version 15.5 utilizing 2 mm craniocaudal and 1 mm axial block margins followed by light optimization in order to reduce modulation. A unique plan optimization methodology, which utilizes a novel shell structure (OptiForR50) for R50% optimization in addition to five consecutive concentric 5 mm shells, was utilized to control dose falloff according to RTOG 0813 and 0915 recommendations. The prescription varied from 34–54 Gy in 1–4 fractions, and the dose objectives were PTV D95% = Rx, PTV Dmax < 140% of Rx, and minimizing the modulation factor. Plan evaluation metrics included modulation factor, CIRTOG, homogeneity index (HI), R50%, D2cm, V105%, and lung V8–12.8Gy (Timmerman Constraint). A random-intercept linear mixed effects model was used with a p ≤ 0.05 threshold to test for statistical significance. Results. The retrospectively generated plans had significantly lower modulation factors (3.65 ± 0.35 versus 4.59 ± 0.54; p < 0.001), lower CIRTOG (0.97 ± 0.02 versus 1.02 ± 0.06; p = 0.001), higher HI (1.35 ± 0.06 versus 1.14 ± 0.04; p < 0.001), lower R50% (4.09 ± 0.45 versus 4.56 ± 0.56; p < 0.001), and lower lungs V8–12.8Gy (Timmerman) (4.61% ± 3.18% versus 4.92% ± 3.37%; p < 0.001). The high dose spillage V105% was borderline significantly lower (0.44% ± 0.49% versus 1.10% ± 1.64%; p = 0.051). The D2cm was not statistically different (46.06% ± 4.01% versus 46.19% ± 2.80%; p = 0.835). Conclusion. Lung SBRT plans with significantly lower modulation factors can be generated that meet the RTOG constraints, using our planning strategy.


  • Open Access

    An Analysis of Risk Factors for Radiation Necrosis Following Cranial Radiation

    by Caleb Nissen, Jun Ying, Madison Newkirk, Ganesh Narayanasamy, Gary Lewis, Fen Xia

    Radiation necrosis in the brain is a frequent complication of brain radiation therapy (RT) and is characterized by various neurological symptoms including cognitive dysfunction, headaches, weakness, apraxia, aphasia, and numbness. These symptoms may be progressive and treatment-resistant. Currently, risk factors for radiation necrosis are not well characterized. The goal of this study is to identify risk factors for cerebral radiation necrosis in order to improve clinicians’ ability to appropriately weigh the risks and benefits of brain RT. A retrospective chart review was performed on patients who were diagnosed with brain tumors and received RT (3D conformal therapy, volumetric modulated arc therapy, stereotactic radiosurgery, or stereotactic radiotherapy) at the University of Arkansas for Medical Sciences from July 1, 2017, to July 1, 2019. Data regarding demographics, characteristics of cancer, chemotherapy status and class, comorbidities, and additional medications of patients were collected via EPIC. Total RT dose, fraction size, volume of brain receiving 12 Gy (V12), and retreatment of locally recurrent tumors were recorded from Eclipse. The diagnosis of radiation necrosis was based on MRI reports that were examined for a time period of 24 months following the completion of radiation treatment and confirmed, when possible, by biopsy. Cases that did not have an MRI available at least two months after the completion of RT were excluded. Statistical association analyses were used to identify candidate risk factors to radiation necrosis. These candidate risk factors were further used to assess their associations to demographics and other characteristics of cancer and treatments. Finally, adjusted and unadjusted logistic regression models were used to predict radiation necrosis using a single risk factor or multiple risk factors. ROC curves were used to evaluate the performance of prediction or discrimination of the logistic regression models. A total of 139 patients were studied. The mean ± standard deviation (SD) for age was 60.4 ± 13.6 years, female:male ratio was 71:68, and White:African American:other race ratio was 112:24:3. A total of 43 (30.9%) patients were diagnosed with radiation necrosis. Radiation adjuvant to surgery, concurrent systemic therapy status, total dose, and V12 were found to be significantly associated with radiation necrosis and considered candidate risk factors of radiation necrosis in the study. Predictive models showed adjusted odds ratios ([aORs] 95% confidence intervals or CIs) of 3.70 (1.01-13.56) and 8.19 (1.78-37.78) with radiation adjuvant to surgery and concurrent systemic therapy, respectively. For every one unit (log-transformed) increase of total dose and V12, the aORs (95% CI’s) were 27.35 (3.74-200.16) and 1.63 (1.15-2.32), respectively. Our study suggested a positive correlation of concurrent systemic therapy status and post-surgical adjuvant RT with the incidence of radiation necrosis. It further demonstrated that greater total RT dose and V12 were related to the risk of developing radiation necrosis following brain RT. Given the findings of this study, the aforementioned factors should be considered when weighing the risk of radiation necrosis with the benefits of treatment.


  • A phantom-based study and clinical implementation of brainlab’s treatment planning system for radiosurgical treatments of arteriovenous malformations

    by Nishan Shrestha, Ganesh Narayanasamy, Faraz Kalantari, Pouya Sabouri, Fen Xia, Su Zhong

    Purpose. Development of a simple, phantom-based methodology allowing for pilot applications for the Elements TPS cranio-vascular module and clinical implementation prior to AVM treatments. Methods. A customized phantom was developed to be visible in MRI and CT images. High resolution digital subtraction angiograms (DSAs) and CT images of the phantom were acquired and imported into the Brainlab Elements treatment planning system. A clinical treatment plan with 5 arcs was generated in cranial vascular planning module and delivered to the phantom using a Varian TrueBeam STx Linac equipped with HD-MLCs and Brainlab ExacTrac imaging system for non-coplanar setup verification. The delivered dose was verified using a calibrated ionization chamber placed in the phantom. Upon verification of the TPS workflow, three patients with AVM who have been treated to date at our center using the Brainlab’s cranial vascular module for AVM are presented here for retrospective review. Results. The difference between the planed and measured dose by the ionization chamber was found to be less than 1%. Following a successful dose verification study, a clinical workflow was created. Currently, three AVM patients have been treated successfully. Clinical aspects of imaging and treatment planning consideration are presented in retrospective setting. Conclusions. Dose verification of the Brainlab Elements cranial vascular planning module for intracranial SRS treatments of AVM on Varian TrueBeam was successfully implemented using a custom-made phantom with <1% discrepancy. The Brainlab Elements’ cranial vascular module was successfully implemented in clinical workflow to treat patients with AVM. This manuscript provides a guideline for clinical implementation of frameless Linac-based AVM treatment using the Brainlab Elements TPS.

  • A dosimetric comparative analysis of Brainlab elements and Eclipse RapidArc for spine SBRT treatment planning

    by Garron Deshazer, Ganesh Narayanasamy, Milan Bimali, Edvaldo Galhardo, Faraz Kalantari, Fen Xia, Jose Peñagarícano, Steven Morrill

    Purpose . This is a dosimetric study comparing stereotactic body radiotherapy (SBRT) plans of spine tumors using Brainlab Elements Spine planning module against Eclipse RapidArc plans. Dose conformity, dose gradient, dose fall-off, and patient-specific quality assurance (QA) metrics were evaluated. Methods:Twenty patients were immobilized in supine position using half Vac-Lok. A prescription dose of 16 Gy in a single fraction was planned for Varian TrueBeam. Conformal arc plans were generated with Pencil beam (PB), MonteCarlo (MC) in Elements, and RapidArc with Acuros XB algorithm in Eclipse using identical treatment geometry. Result s. Eclipse, Elements PB, and Elements MC generated dosimetrically conformal plans having Inverse Paddick Conformity Index (IPCI) 95% points passing the gamma QA criteria at 3%/2 mm. Conclusion . All treatment plans achieved clinically acceptable target coverage >95% and meet spinal cord dose limits. Smart optimization in Brainlab Elements spine module produced dosimetrically superior plans by better spinal cord sparing.


  • Evaluation of the Dose Delivery Consistency and Its Dependence on Imaging Modality and Deformable Image Registration Algorithm in Prostate Cancer Patients

    by Jacob Hammers, Sara Pirozzi, Ganesh Narayanasamy, Daniel Lindsay, Orit Kaidar-Person, Xianming Tan, Ronald C. Chen, Shiva K. Das, Panayiotis Mavroidis


  • Computational simulator that calculates tumor control probability in a tumor heterogeneously irradiated for fractionated radiation oncology treatments

    by Terman Frometa-Castillo, Anil Pyakuryal, Ganesh Narayanasamy, Amadeo Wals-Zurita, Raul Piseaux-Aillon, Asghar Mesbahi

    Although in the ionizing radiation field many concepts and processes are currently recognized as radiobiological, there are also probabilistic ones, and a probabilistic treatment makes a better understanding about them. The purpose of this study is to develop a new radiobiological simulator that calculates the tumor control probability (TCP) for a tumor heterogeneously irradiated from a fractioned treatment. The three possible types of cells and the results of interactions of ionizing radiation with each cell of a determined volume are analyzed. For an irradiated region with a dose per fraction d, the simulator determines the radiation biological effects using the cell kill (K) and cell sub-lethal damage, volume, cell density, cell repair of damaged cells during the interfractions, and number of fractions. K is determined from its probabilistic complement, the cell survival (S), described with the linear-quadratic (LQ) S(d) model as K = 1 −LQ S(d). TCP is calculated from computational simulations as in the ratio of simulations with K = 100% and their total. This application opens new avenues for theoretical and experimental investigations concerning simulations of radiation treatments, and methodologies for therapy optimizations. Our simulator represents a novel methodology as TCP is calculated without analytical formulas, but based on its own probabilistic definition.


  • Open Access

    Cleaning the dose falloff in lung SBRT plan

    by Dharmin Desai, Ganesh Narayanasamy, Milan Bimali, Ivan Cordrey, Hisham Elasmar, Senthamizhchelvan Srinivasan, Ellis Lee Johnson

    Purpose: To investigate a planning technique that can possibly reduce low‐to‐intermediate dose spillage (measured by R50%, D2cm values) in lung SBRT plans.Materials and Methods: Dose falloff outside the target was studied retrospectively in 102 SBRT VMAT plans of lung tumor. Plans having R50% and/or D2cm higher than recommended tolerances in RTOG protocols 0813 and 0915 were replanned with new optimization constraints using novel shell structures and novel constraints. Violations in the RTOG R50% value can be rectified with a dose constraint to a novel shell structure (“OptiForR50”). The construction of structure OptiForR50% and the novel optimization criteria translate the RTOG goals for R50% into direct inputs for the optimizer. Violations in the D2cm can be rectified using constraints on a 0.5 cm thick shell structure with inner surface 2cm from the PTV surface. Wilcoxon signed‐rank test was used to compare differences in dose conformity, volume of hot spots, R50%, D2cm of the target in addition to the OAR doses. A two‐sided P‐value of 0.05 was used to assess statistical significance.Results: Among 102 lung SBRT plans with PTV sizes ranging from 5 to 179 cc, 32 plans with violations in R50% or D2cm were reoptimized. The mean reduction in R50% (4.68 vs 3.89) and D2cm (56.49 vs 52.51) was statistically significant both having P < 0.01. Target conformity index, volume of 105% isodose contour outside PTV, normal lung V20, and mean dose to heart and aorta were significantly lowered with P < 0.05.Conclusion: The novel planning methodology using multiple shells including the novel OptiForR50 shell with precisely calculated dimensions and optimizer constraints lead to significantly lower values of R50% and D2cm and lower dose spillage in lung SBRT plans. All plans were successfully brought into the zone of no RTOG violations.


  • Definitive single fraction stereotactic ablative radiotherapy for inoperable early-stage breast cancer: A case report

    by Manasa Veluvolu, Mausam Patel, Ganesh Narayanasamy, Thomas Kim

    We review a case of inoperable early stage breast cancer treated definitively with the use of stereotactic ablative radiotherapy (SABR). A 57-year-old female with a history of decompensated cirrhosis with early stage breast cancer was treated with 25 Gy in one fraction. At her 7-month follow up visit, there was a complete resolution of disease on imaging. This case represents a novel approach for the treatment of breast cancer with SABR when surgery is contraindicated.


  • Open Access

    Radiosurgery for mesial temporal lobe epilepsy following ROSE trial guidelines — A planning comparison between Gamma Knife, Eclipse, and Brainlab

    by Ganesh Narayanasamy, Steven Morrill, David Cousins, Joshua Liu, Garron Deshazer, Wesley Garner, Edvaldo Galhardo, Demitre Serletis, Jose Penagaricano

    Purpose: This study aims to compare stereotactic radiosurgery (SRS) planning of epilepsy that complies with Radiosurgery or Open Surgery for Epilepsy (ROSE) guidelines in GammaKnife, non‐coplanar conformal (NCC) plan in Eclipse, dynamic conformal arc (DCA) plan in Brainlab, and a volumetric modulated arc therapy (VMAT) plan in Eclipse.Methods: Twenty plans targeting Mesial temporal lobe epilepsy (MTLE) was generated using GammaKnife, Eclipse with 20 NCC beams, Brainlab with 5 DCA, and Eclipse VMAT with 4 arcs observing ROSE trial guidelines. Multivariate analysis of variance and Wilcoxon signed‐rank test were used to compare dosimetric data of the plans and perform pairwise comparison, respectively.Results: The plans obeyed the recommended prescription isodose volume (PIV) within 5.5–7.5 cc and maximum doses to brainstem, optic apparatus (OA) of 10 and 8 Gy, respectively, for a prescription dose of 24 Gy. The volumes of the target were in the range 4.0–7.4 cc. Mean PIV, maximum dose to brainstem, OA were 6.5 cc, 10 Gy, 7.9 Gy in GammaKnife; 7.2 cc, 6.1 Gy, 4.5 Gy in Eclipse NCC; 7.2 cc, 6.4 Gy, 5.7 Gy in Brainlab DCA; and 5.2 cc, 8.4 Gy, 6.1 Gy in Eclipse VMAT plans, respectively. Multivariate analysis of variance showed significant differences among the 4 SRS planning techniques (P‐values < 0.01).Conclusions: Among the 4 SRS planning methods, VMAT with least PIV and acceptable maximum doses to brainstem and OA showed highest compliance with ROSE trial. Having the most conformal dose distribution and least dose inhomogeneity, VMAT scored higher than GK, Eclipse NCC, and Brainlab DCA plans.